All In Biotech

Drug Trial Radar · NCT07059312

A Phase 1 Study of JADE101 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Aug 17, 2025

Primary completion

Oct 21, 2026

Study completion Oct 21, 2026

Sponsor

Lead sponsor
Jade Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jul 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • JADE101Drug

    JADE101 is supplied as sterile solution to be administered by SC injection.

  • PlaceboDrug

    Placebo solution to be administered at a matching volume by SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy ParticipantsTime frame: Day 1 through 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NZCR

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.